McKesson Closes Strategic Investment with Apollo Funds for Minority Interest in Medical-Surgical Solutions

IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) announced today the successful completion of the previously announced minority ownership interest investment from funds managed by affiliates of Apollo (“Apollo Funds”) in McKesson's Medical-Surgical Solutions (“MMS”) business on June 1, 2026. This transaction represents a key milestone in McKesson's intention to separate MMS into an independent, publicly traded company, and positions the business for long-term growth. Apollo Fund.

Business Wire • Jun 2, 2026

McKesson Corporation (MCK) Is a Trending Stock: Facts to Know Before Betting on It

Zacks.com users have recently been watching McKesson (MCK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks Investment Research • May 27, 2026

Baron Health Care Fund Q1 2026 Portfolio Activity

During the quarter, we added 9 new positions and exited 11 positions, bringing the number of positions in the Fund to 41. We reacquired shares of Natera, Inc., a diagnostics company that provides testing services in the oncology, prenatal, and organ transplant settings. We added to the Fund's investment in BillionToOne, Inc., a diagnostics company that is disrupting the market with more accurate prenatal and oncology genetic tests.

Seeking Alpha • May 27, 2026

Here's Why You Should Retain McKesson Stock in Your Portfolio for Now

McKesson's oncology growth, GLP-1 momentum and RxTS expansion support earnings strength, but pricing reform and margin pressures pose risks.

Zacks Investment Research • May 22, 2026

McKesson Corporation (MCK) is Attracting Investor Attention: Here is What You Should Know

McKesson (MCK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Zacks Investment Research • May 14, 2026

McKesson Corporation (MCK) Presents at Bank of America Global Healthcare Conference 2026 Transcript

McKesson Corporation (MCK) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seeking Alpha • May 12, 2026

McKesson Q4 Earnings Call Highlights

McKesson NYSE: MCK reported a stronger fiscal fourth quarter and full fiscal 2026 performance, with executives pointing to growth across its oncology, multispecialty, pharmaceutical distribution and prescription technology businesses, while outlining plans for continued earnings growth in fiscal 2027.

MarketBeat • May 11, 2026

MCK Stock Falls Despite Q4 Earnings Beat, Sales Miss, Margins Up

McKesson beats Q4 EPS estimates as oncology and specialty distribution growth offset revenue miss and lift segment margins.

Zacks Investment Research • May 8, 2026

McKesson expects 2027 profit slightly above estimates on drug distribution strength

McKesson forecast 2027 profit slightly above Wall Street expectations after beating first-quarter profit estimates ​on Thursday, as the U.S. drug distributor ‌banks on strength in its oncology and specialty drug businesses.

Reuters • May 7, 2026

McKesson Corporation (MCK) Q4 2026 Earnings Call Transcript

McKesson Corporation (MCK) Q4 2026 Earnings Call Transcript

Seeking Alpha • May 8, 2026